12 results about "Insulin resistance" patented technology

The application discloses a composition containing burdock polysaccharide for reducing blood sugar of type 2 diabetes patients and a preparation method and application thereof, and belongs to the technical field of medicine and food. The composition contains burdock polysaccharide, chitooligosaccharide, chlorogenic acid, epicatechin, resveratrol, ginsenoside Rd, and vitamin D, vitamin B1, vitamin B6, vitamin B12, magnesium glycinate and thaumatin protein. The application takes burdock polysaccharide as a core long-acting component, takes chitooligosaccharide as a short-acting synergistic component, constructs a long-short-acting synergistic blood sugar reducing system, and realizes the organic combination of rapid blood sugar reduction and stable blood sugar control. Experiments show that the composition can significantly reduce the fasting blood sugar of type 2 diabetes model rats, improve insulin resistance and glucose tolerance, reduce blood lipid and inflammatory factor levels, and reduce oxidative stress damage. The alpha-glucosidase inhibitory activity and in-vivo comprehensive blood sugar reducing effect of the composition are better than those of single burdock polysaccharide, and the composition has good taste and is suitable for long-term use of diabetes patients.

The application belongs to the field of functional substance research, and particularly relates to a corn extract for promoting GLP-1 secretion, and a preparation method and application thereof. The corn extract provided by the application is a dried product obtained by ultrasonic extraction of a dried powder of fresh corn kernels after room temperature soaking in ethanol or an ethanol aqueous solution; the fresh corn comprises yellow sweet corn; the temperature of the ultrasonic extraction is 30-60 DEG C; the power of the ultrasonic extraction is 50-150 W; and the time of the ultrasonic extraction is 30-90 min. The preparation method of the corn extract is simple and easy to implement, and can effectively reduce the production cost of functional ingredients. The corn extract can effectively promote the secretion of GLP-1 by intestinal L cells in both healthy and insulin-resistant states, and simultaneously improve cell viability.

The application discloses a compound cereal powder for controlling blood sugar and reducing blood sugar, a preparation method and application thereof. The compound cereal powder comprises, in percentage by weight, 10-30% of soybean dietary fiber, 10-25% of resistant dextrin, 5-20% of soybean protein isolate powder, 5-15% of oat powder, 5-15% of black bean powder, 3-12% of purple sweet potato powder, 3-12% of oatmeal, 0.5-5% of poria cocos powder, 0.5-5% of yam powder, 0.5-5% of honeysuckle powder, 1-8% of konjac powder, 0.5-5% of medlar powder, 0.5-5% of mulberry leaf powder, 0.5-5% of rhizoma polygonati powder, compound vitamins, calcium carbonate, zinc gluconate and sodium carboxymethyl cellulose. The preparation method comprises the following steps: low-temperature baking and curing cereal raw materials, uniformly mixing by a three-dimensional mixer, screening and sterilizing, and sterilely sub-packaging. The compound cereal powder controls blood sugar and reduces blood sugar through multiple mechanisms such as a dietary fiber physical barrier, alpha-glucosidase inhibition, improvement of insulin resistance and supplement of trace elements, is comprehensive in nutrition, good in taste, and is suitable for people with diabetes and pre-diabetes as a meal replacement or a functional food for assisting blood sugar reduction.

The application relates to the technical field of compound medicines, and discloses application of a compound external-use patch for preventing and treating diabetic peripheral neuropathy, wherein the compound external-use patch comprises a gel base and dry extract and volatile oil doped into the gel base, the dry extract and the volatile oil are derived from a compound, and the compound is composed of 10-20 parts of cinnamon, 8-12 parts of asarum, 8-12 parts of evodia, 8-12 parts of chuanxiong and 0.2-0.8 parts of borneol in terms of weight parts. The compound external-use patch of the application is locally pasted on acupoints or joints of DPN rats, can reduce the blood sugar level of diabetic peripheral neuropathy rats, increase the insulin level, improve insulin resistance, prolong the latent period of hot stimulation foot withdrawal, increase the nerve conduction velocity, maintain the normal morphology and function of nerve cells, and therefore can prevent and inhibit the generation and deterioration of diabetic peripheral neuropathy; and the compound external-use patch improves the safety and convenience of patients in taking medicine compared with oral medicine.

Methods of predicting insulin resistance in a subject are provided. The methods include measuring interstitial fluid glucose in the subject over a period of time to obtain a plurality of glucose values (G(tn)); fitting the measured plurality of glucose values (G(tn)) to a glucose-insulin response model to calculate a plurality of subject-specific parameters, the glucose-insulin response model comprising a modified Lotka-Volterra system of equations for the glucose-insulin response pair (G(t), I(t)); and comparing at least one of the calculated subject-specific parameters to a set threshold value to predict insulin resistance in the subject. Systems for predicting insulin resistance in a subject are also provided. The systems include a continuous glucose monitoring (CGM) sensor and a computation device.

The invention is concerned with a bacterium comprising a phytate to 3-hydroxoypropionate pathway gene set that allows said bacterium to convert phytate to 3-hydroxypropionate or a salt or ester thereof. The bacterium can be used as a probiotic or supplement to promote production of propionate in the Gl tract, thereby preventing and / or treating conditions or diseases that benefit from the production of propionate, for example metabolic disease, metabolic syndrome, obesity, insulin resistance or insulin resistance-related conditions, particularly dyslipidemia, (M)ASLD-(M)ASH, type 2 diabetes mellitus and insulin-resistance in endocrine diseases.

This invention belongs to the field of nutritional supplement technology, specifically relating to a hemp seed dietary fiber composition, its products, and applications. The composition comprises hemp seed dietary fiber; based on the total weight of the raw materials (100%), the hemp seed dietary fiber accounts for 10% to 50% of the total weight. This invention uses hemp seed, a food and medicine homology source, as the active ingredient in the composition, ensuring high safety. This composition achieves synergistic effects through multiple mechanisms, including improving gut health, regulating glucose and lipid metabolism, and modulating the FFAR2-RYR-MYOG pathway. It can significantly improve muscle function and increase muscle mass, effectively preventing and improving sarcopenia. It is particularly suitable for the elderly and those intolerant to high-protein diets or with insulin resistance, solving the problems of limited effectiveness, low compliance, and high safety risks associated with existing intervention methods.

This invention belongs to the field of fungal polysaccharide application technology, specifically relating to a method for preparing and applying polysaccharide from *Boletus globosum*. Crude polysaccharide was extracted from the fruiting body of *Boletus globosum* using hot water extraction, and purified using DEAE-52 cellulose column chromatography. Subsequently, by establishing an alcohol-induced liver injury model, it was found that NOP-1 significantly reduced ALT and AST levels, while simultaneously decreasing MDA content and increasing SOD activity and GSH levels, indicating that NOP-1 can inhibit lipid peroxidation, enhance the antioxidant defense capacity of hepatocytes, and maintain hepatocyte membrane integrity. A HepG2 cell IR model was constructed using a high-glucose, high-insulin combined induction method, determining the optimal dosage of NOP-1. ‑6 Treatment of HepG2 cells with mol / L insulin for 24 h successfully induced insulin resistance. Glucose consumption experiments in IR HepG2 cells demonstrated that NOP-1 significantly enhanced the glucose consumption capacity of insulin-resistant cells, exhibiting significant in vitro hypoglycemic activity.

This invention discloses a high-performance bio-based probiotic granule, its preparation method, and its application in improving obesity and type 2 diabetes. The high-performance bio-based probiotic granule is *Lactobacillus rhamnosus* loaded with Prussian blue treated with hydrochloric acid, and its concentration is 1×10⁻⁶. 8 –5×10 9 The concentration of Prussian blue treated with hydrochloric acid is CFU / mL, and the loading of Prussian blue is 0.5–2.0 mg / mL. This invention utilizes probiotic carriers to achieve targeted delivery of functional nanomaterials, and enhances the survival rate of probiotics in harsh environments through nanomaterials, endowing them with strong antioxidant functions, thereby synergistically exerting a comprehensive therapeutic effect of lowering blood sugar, improving insulin resistance, regulating gut microbiota, and alleviating obesity.

The invention is in the field of biomedicine; and relates to Lacticaseibacillus paracasei subsp. tolerans, and a specific bacterial strain or a variant thereof, and their use in the treatment of insulin resistance syndrome, polycystic ovary syndrome, insulin resistance related infertility, gestational diabetes, obesity, and proinflammatory conditions. The invention also relates to a biologically pure culture, or the composition, or the pharmaceutical product, or the pharmaceutical composition, or the nutraceutical composition, or the food supplement, the feed, or the nutritional product comprising the specific bacterial strain or variant thereof, and a therapeutic method comprising administering the specific bacterial strain, or the biologically pure culture, or the composition, or the pharmaceutical product, or the pharmaceutical composition, or the nutraceutical composition, or the food supplement, the feed, or the nutritional product comprising the bacterial strain or a variant thereof.

This invention relates to the field of biomedical technology, and particularly to a method and application for identifying active ingredients for the prevention and treatment of diabetes from non-medicinal Astragalus membranaceus slices. The method includes: first, qualitative and quantitative analysis of the chemical components of Astragalus membranaceus and longan slices; second, evaluation of its hypoglycemic efficacy using a diabetic rat model to verify the effects of Astragalus membranaceus and longan slices in lowering blood sugar, improving insulin resistance, and reducing inflammation; and finally, integration of non-targeted and pseudo-targeted metabolomics technologies to systematically identify the core active ingredients in key pathways for the prevention and treatment of diabetes by analyzing the correlation between chemical components and efficacy indicators. This invention not only reveals the main pharmacodynamic substances of Astragalus membranaceus in the prevention and treatment of diabetes, but also provides a theoretical basis and technical support for the development of related functional products or innovative drugs, and for comprehensively improving the utilization efficiency and economic value of Astragalus membranaceus resources.

The present invention relates to an AMPK activator containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient and use thereof. The present invention also relates to a composition for improving insulin resistance containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient and use thereof. The present invention relates to a composition for preventing or treating obesity or related metabolic diseases containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient.